SARS-CoV-2 Vaccination and Hidradenitis Suppurativa: Role of Vaccination in Disease Activity

This study investigated the impact of SARS-CoV-2 vaccination on disease activity in 222 patients with Hidradenitis Suppurativa (HS). It found that 9.5% of patients experienced flares within 2 weeks post-vaccination, with a higher incidence in those with advanced Hurley stages. No significant association was found between the type of vaccine and flare occurrence, although biologic treatments were linked to a reduced risk of flares. The study concluded that SARS-CoV-2 vaccination is generally safe for HS patients, aligning with other research indicating no significant increase in flare risk. However, the study's retrospective nature and lack of a control group were noted as limitations.